Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04295850 · ClinicalTrials.gov registry record
Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)
A clinical trial of Preeclampsia, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 130
- Enrollment target
- 1
- Study location
NCT04295850: Completed study of Preeclampsia, sponsored by Thomas Jefferson University.
NCT04295850 is a study of Preeclampsia that has completed, run by Thomas Jefferson University. The registered enrollment target is 130 participants, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04295850, a study of Preeclampsia, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The results of this proposal will provide necessary data for prospective study on individualized aspirin dose adjustment for prevention of HDP.
Primary Outcome
Difference in first trimester PFA-100 closure time between patients started on aspirin who do and do not develop HDP
Conditions Studied
Interventions
- DRUG Aspirin 81 mg
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2023-06-30 |
What the finished NCT04295850 record still lists
NCT04295850 is an observational study that tracks outcomes without assigning an intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Aspirin 81 mg is the first listed.
NCT04295850 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04295850 about?
NCT04295850 is a clinical study titled "Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)". This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The result...
What is the current status of trial NCT04295850?
This trial is currently completed. The enrollment target is 130 participants. The study started on 2020-08-21. Estimated completion is 2023-06-30.
What conditions does trial NCT04295850 study?
This clinical trial studies the following conditions: Preeclampsia.
What interventions are being tested in trial NCT04295850?
The interventions under investigation include: Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT04295850?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04295850 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04295850's enrollment target sits among peer trials
130 26th of 48 higher than 22 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI